TMFX - ETF AI Analysis
Top Page
Motley Fool Next Index ETF (TMFX)
Rating:69Neutral
Price Target:―
Positive Factors
Strong Recent Monthly Rebound
The ETF has shown a solid gain over the past month, suggesting some positive short-term momentum after earlier weakness.
Broad Sector Diversification
Holdings are spread across technology, health care, consumer, industrial, and financial companies, which helps reduce the impact of trouble in any one sector.
Several Strong Top Holdings
A number of the largest positions, such as Interactive Brokers, Astera Labs, Cboe Global Markets, MasTec, Casey’s General, and Biogen, have delivered strong year-to-date performance that supports the fund.
Negative Factors
Weak Year-to-Date and Recent Quarter Performance
The ETF is slightly down so far this year and has struggled over the last three months, which may concern investors looking for steadier returns.
High U.S. Market Concentration
With nearly all assets invested in U.S. companies, the fund offers little geographic diversification and is heavily tied to the U.S. market’s fortunes.
Several Lagging Top Holdings
Some key positions, including Reddit, Copart, Cognizant, and Veeva Systems, have shown weak year-to-date performance, which can drag on overall results.
TMFX vs. SPDR S&P 500 ETF (SPY)
AUM33.30M
RegionNorth America
Expense Ratio0.50%
Beta1.06
IssuerMotley Fool
Inception DateDec 29, 2021
Dividend Yield0.05%
Asset ClassEquity
Index TrackedMotley Fool Next Index - Benchmark TR Gross
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume4,443
30 Day Avg. Volume5,038
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
27.77Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering197
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TMFX Summary
TMFX is the Motley Fool Next Index ETF, which follows the Motley Fool Next Index and focuses on U.S. mid-size and smaller companies that could become tomorrow’s leaders. It holds a wide mix of sectors, including technology, health care, and consumer companies. Well-known names in the fund include Biogen and Cognizant. Someone might invest in TMFX to seek long-term growth and to diversify beyond the biggest, most familiar large-cap stocks. A key risk is that smaller and fast-growing companies can be more volatile, so the ETF’s price can rise and fall more sharply than the overall market.
How much will it cost me?The Motley Fool Next Index ETF (TMFX) has an expense ratio of 0.50%, meaning you’ll pay $5 per year for every $1,000 invested. This is higher than average for ETFs because it is actively managed, focusing on identifying high-growth and innovative companies rather than tracking a broad index. Active management typically involves more research and strategy, which increases costs.
What would affect this ETF?The TMFX ETF, which focuses on mid-cap and small-cap companies in the U.S., could benefit from growth in innovative sectors like technology and health care, as these industries often drive market disruption and long-term expansion. However, its exposure to consumer cyclical and financial sectors may face challenges during economic downturns or periods of high interest rates, which can impact consumer spending and borrowing. Additionally, regulatory changes or shifts in market sentiment toward smaller companies could influence the ETF's performance positively or negatively.
TMFX Top 10 Holdings
TMFX is leaning into U.S. mid- and small-cap growth, with tech and infrastructure names setting the tone. Astera Labs is one of the fund’s key engines, rising on excitement around high-growth chip connectivity, while Sterling Infrastructure and MasTec add steady, construction-driven momentum. Interactive Brokers and Reddit are also climbing, giving the fund a boost from digital finance and online platforms. On the flip side, Copart has been lagging, acting as a small brake on performance. Overall, the ETF is a U.S.-focused, innovation-heavy bet on tomorrow’s market leaders.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Reddit Inc Class A | 1.75% | $590.61K | $34.88B | 24.16% | 75 Outperform | |
| Workday | 1.72% | $579.97K | $35.76B | -37.01% | 73 Outperform | |
| Casey's General | 1.53% | $514.42K | $31.79B | 67.19% | 68 Neutral | |
| Dexcom | 1.47% | $494.32K | $29.58B | -9.92% | 79 Outperform | |
| EQT | 1.46% | $493.11K | $31.00B | -8.39% | 76 Outperform | |
| Biogen | 1.46% | $492.42K | $30.41B | 62.98% | 74 Outperform | |
| Coupang | 1.45% | $488.94K | $29.83B | -47.63% | 60 Neutral | |
| Veeva Systems | 1.44% | $485.53K | $31.74B | -29.75% | 66 Neutral | |
| Cboe Global Markets | 1.44% | $484.08K | $28.61B | 17.76% | 75 Outperform | |
| GE Healthcare Technologies Inc | 1.37% | $460.29K | $28.69B | -15.28% | 78 Outperform |
TMFX Technical Analysis
Neutral
―
Price Trends
22.34
Positive
21.54
Positive
21.57
Positive
Market Momentum
0.17
Positive
45.27
Neutral
7.48
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For TMFX, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 22.94, equal to the 50-day MA of 22.34, and equal to the 200-day MA of 21.57, indicating a neutral trend. The MACD of 0.17 indicates Positive momentum. The RSI at 45.27 is Neutral, neither overbought nor oversold. The STOCH value of 7.48 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TMFX.
TMFX Peer Comparison
Comparison Results
Performance Comparison
TMFX
Motley Fool Next Index ETF
22.54
1.26
5.92%
OASC
OneAscent Small Cap Core ETF
―
―
―
SMOX
Horizon Small/Mid Cap Core Equity ETF
―
―
―
FSCS
First Trust Smid Capital Strength Etf
―
―
―
HSMV
First Trust Horizon Managed Volatility Small/Mid ETF
―
―
―
MYLD
Cambria Micro and SmallCap Shareholder Yield ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents